日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance

HCK/BTK 抑制剂 KIN-8194 对 MYD88 驱动的淋巴瘤有效,并可克服突变的 BTKCys481 依鲁替尼耐药性

Guang Yang, Jinhua Wang, Li Tan, Manit Munshi, Xia Liu, Amanda Kofides, Jiaji G Chen, Nicholas Tsakmaklis, Maria G Demos, Maria Luisa Guerrera, Lian Xu, Zachary R Hunter, Jinwei Che, Christopher J Patterson, Kirsten Meid, Jorge J Castillo, Nikhil C Munshi, Kenneth C Anderson, Michael Cameron, Sara J

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

SYK 由突变的 MYD88 激活,并在 MYD88 驱动的 B 细胞淋巴瘤中驱动促生存信号传导

Manit Munshi, Xia Liu, Jiaji G Chen, Lian Xu, Nickolas Tsakmaklis, Maria G Demos, Amanda Kofides, Maria Luisa Guerrera, Cristina Jimenez, Gloria G Chan, Zachary R Hunter, M Lia Palomba, Kimon V Argyropoulos, Kirsten Meid, Andrew Keezer, Joshua Gustine, Toni Dubeau, Jorge J Castillo, Christopher J Pa

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

在 MYD88 驱动的 B 细胞淋巴瘤中,促生存激酶 HCK 的表达需要 PAX5 和突变的 MYD88 信号传导

Xia Liu, Jiaji G Chen, Manit Munshi, Zachary R Hunter, Lian Xu, Amanda Kofides, Nickolas Tsakmaklis, Maria G Demos, Maria Luisa Guerrera, Gloria G Chan, Cristina Jimenez, Christopher J Patterson, Kirsten Meid, Andrew Keezer, Jorge J Castillo, Steven P Treon, Guang Yang

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

BTKCys481Ser 通过 ERK1/2 驱动伊布替尼耐药性,并通过旁分泌机制保护 BTKwild 型 MYD88 突变细胞

Jiaji G Chen, Xia Liu, Manit Munshi, Lian Xu, Nicholas Tsakmaklis, Maria G Demos, Amanda Kofides, Maria Luisa Guerrera, Gloria G Chan, Christopher J Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, Patricia Severns, Jorge J Castillo, Zachary R Hunter, Jinhua Wang, Sara J Buhrlage, Nathanael S G